跳至主要内容
临床试验/NCT06327191
NCT06327191招募中不适用

EMERGE Mothers and Kids: a Longitudinal Cohort Study of Mothers and Kids Enrolled in the Randomized Placebo Controlled Trial of Metformin in Women With GDM (EMERGE)

National University of Ireland, Galway, Ireland1 个研究点 分布在 1 个国家目标入组 321 人开始时间: 2024年7月9日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
321
试验地点
1
主要终点
To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of metabolic syndrome.

研究概览

简要总结

The EMERGE Mothers and Kids study is a follow-up to the EMERGE trial of women with GDM (N=535) that aimed to determine the effect of the addition of metformin compared to placebo on insulin initiation rates, maternal weight gain and perinatal morbidity and mortality.

The primary objectives of the EMERGE Mothers and Kids follow up study are:

  1. to determine whether treatment with metformin leads to a reduction in maternal disorders of glucose, metabolic syndrome, obesity, hypertension and lipids at up to 10 years post the index pregnancy;
  2. to examine the impact of metformin on maternal anxiety, depression, quality of life and breast feeding duration;
  3. to examine whether exposure to metformin leads to a reduction in obesity in the offspring at follow up;
  4. to determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Participation in the original EMERGE trial and consenting to further follow up.

排除标准

  • EMERGE trial participants who did not provide consent for further follow up studies.

结局指标

主要结局

To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of metabolic syndrome.

时间窗: Up to 10 years post the index pregnancy

Metabolic syndrome is defined as the presence of \>3 of the following risk factors (International Diabetetes Foundation 2009) * Fasting glucose \>5.6 mmol/L or diagnosed diabetes * High density lipoprotein (HDL) cholesterol of \<1.3 mmol/L or drug treatment for low HDL cholesterol * Triglyceride level of \>1.7 mmol/L or drug treatment for elevated triglycerides * Waist circumference of \>80cm * Hypertension with a blood pressure of \> 130/85 mmHg or drug treatment for hypertension

To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.

时间窗: Up to 10 years post the index pregnancy

Obesity will be defined as a BMI of \>95th percentile or BMI \> 30 kg/m2 (whichever is lower) for children 2 years and older. Overweight will be defined as a BMI of \>85th percentile. Weight for height gender specific growth charts will be used for children \<2 years of age and a weight-for-height which is \>95th centile will be considered obese. Overweight wil be defined as a BMI of \>85th percentile.

To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of disorders of glucose metabolism at follow up..

时间窗: Up to 10 years post the index pregnancy

This will be evaluated using a 75g oral glucose tolerance test (OGTT) and a haemoglobin A1c (HbA1c). Cutoffs for diabetes, imparied fasting gluocse and impaired glucose tolerance will be in line with the American Diabetes Association diagnostic criteria (ADA 2023).

To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of hypertension.

时间窗: Up to 10 years post the index pregnancy

Hypertension is defined as a blood pressure of \> 130 mmHg systolic or \>80 mmHg diatolic (Whelton 2017).

To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces rates of OW and OB at follow up.

时间窗: Up to 10 years post the index pregnancy

Definitions of overweight and obesity are a body mass index of \>25 kg/m2 and \>30 kg/m2, respectively.

To examine the associations of GDM diagnosis, sum of fasting, 1-hour, and 2-hour glucose z-scores after 75-g load, insulin sensitivity, and lipid levels at 24-32 weeks' gestation with lipid levels at up to 10 years postpartum.

时间窗: Up to 10 years post the index pregnancy

Lipid levels will be assessed by measuring a fasting sample and will be analysed using local assays.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fidelma Dunne

Professor

National University of Ireland, Galway, Ireland

研究点 (1)

Loading locations...

相似试验